Mini-Sintrom (Acenocoumarol)

Acenocoumarol, the active ingredient in Mini-Sintrom, is a Vitamin K antagonist presented as an oral tablet for oral administration. It is employed to prevent and treat thromboembolic disorders, such as deep‑vein thrombosis and pulmonary embolism, in adult patients.

GNH USA supplies Mini‑Sintrom as a licensed, GDP‑compliant international pharmaceutical supplier, providing the product to hospitals, pharmacies and clinics worldwide, with a focus on EU‑origin quality standards and reliable global logistics. All shipments meet applicable regulatory requirements and are supported by comprehensive documentation.

Acenocoumarol is used in the management of thromboembolic conditions, acting as an oral anticoagulant to reduce clot formation.

- Deep‑vein thrombosis: prevention of clot extension and recurrence. - Pulmonary embolism: treatment to dissolve existing clots and prevent new ones. - Atrial fibrillation (non‑valvular): stroke risk reduction through anticoagulation. - Post‑operative orthopedic surgery: prophylaxis against venous thromboembolism.

Acenocoumarol may cause a range of adverse reactions, from mild to severe, related primarily to its anticoagulant activity.

Common Side Effects: - Minor bleeding: gums, nosebleeds, or easy bruising. - Gastrointestinal discomfort: nausea, abdominal pain or dyspepsia. - Headache: mild to moderate intensity. - Skin rash: localized erythema or pruritus. - Elevated liver enzymes: mild transaminase increase.

Serious or Rare Side Effects: - Severe hemorrhage: intracranial or gastrointestinal bleeding. - Skin necrosis: painful, purpuric lesions, often on fatty areas. - Anaphylactic reaction: rare hypersensitivity with airway compromise. - Hepatotoxicity: marked liver injury with jaundice.

When prescribing Acenocoumarol, clinicians should consider several safety measures to minimize risk.

- Baseline INR monitoring: establish therapeutic range before initiation. - Dose adjustments: modify based on regular INR values and clinical response. - Liver function assessment: evaluate hepatic status prior to therapy. - Concomitant anticoagulants: avoid combining with other blood thinners unless medically justified. - Pregnancy and lactation: use only if benefits outweigh potential fetal or infant risks. - Store at ambient temperature: keep below 25 °C in the original container, protected from moisture and light.

Acenocoumarol interacts with a variety of medicines that can alter its anticoagulant effect.

Major Interactions (Avoid): - Strong CYP2C9 inhibitors (e.g., fluconazole, amiodarone): may cause excessive anticoagulation. - Antiplatelet agents (e.g., clopidogrel, aspirin): increase bleeding risk. - Non‑steroidal anti‑inflammatory drugs (NSAIDs): potentiate hemorrhagic complications. - Certain antibiotics (e.g., trimethoprim‑sulfamethoxazole): enhance anticoagulant effect.

Moderate Interactions (Monitor Closely): - Vitamin K‑rich foods or supplements: may reduce drug efficacy. - Herbal products (e.g., ginkgo, garlic): can modestly increase bleeding tendency. - Diuretics (e.g., furosemide): may affect plasma concentration. - Thyroid hormones: may alter metabolism and INR stability.